Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Danaos Corporation (DAC) vs Twist Bioscience Corp (TWST) Price & Performance

Danaos CorporationTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Danaos Corporation vs Twist Bioscience Corp — how do they compare? Danaos Corporation trades at $138.27 (market cap $2.46B), while Twist Bioscience Corp trades at $124.89 (market cap $7.72B). The key difference: Twist Bioscience Corp is far larger — about 3.1× Danaos Corporation's market cap, and Danaos Corporation pays a 2.67% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

DACTWST
Market Cap
$2.46B$7.72B
Sector
TechnologyHealth
52-Week High
$143.15$124.88
52-Week Low
$84.05$24.16
Enterprise Value
$2.44B$7.65B
Dividend Yield
2.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Danaos Corporation

Danaos Corporation (DAC) trades at $137.35, down 0.7% on the day, but maintains strong technical and fundamental momentum. The stock shows a bullish technical signal with key support at $133 and resistance at $138. Fundamentally, DAC demonstrates exceptional profitability with a 51.26% net income margin and attractive valuation metrics including a P/E of 4.57 and P/B of 0.61. Recent Q2 2026 earnings beat expectations with EPS of $7.29 versus $6.80 expected, continuing a pattern of strong quarterly performance.

DAC presents a compelling value opportunity with deep discount to book value and consistent earnings outperformance. The company's record $4.6 billion contracted revenue backlog provides visibility, while quarterly dividends of $0.90 per share enhance shareholder returns. Primary risks include shipping industry cyclicality and capital expenditure requirements for fleet expansion. Analyst sentiment is evenly split between Buy and Hold ratings, reflecting the stock's value proposition balanced against sector dynamics.

Twist Bioscience Corp

TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.

The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.

Returns comparison

Trailing returns across standard periods

About Danaos Corporation

Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.

Read more on DAC

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST